Outcome of Cardiomyopathic Adults Admission in ICU.

Not yet recruiting

• Conditions: Cardiomyopathies

• Registration Number: NCT05567445
• Lead Sponsor: Assiut University

Brief Summary

To study the outcome of the cardiac function, and clinical status of the patiants with cardiomyopathy who are admitted in the I.C.U.

Detailed Description

Heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles, and peripheral oedema). It is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise. Identification of the aetiology of the underlying cardiac dysfunction is mandatory in the diagnosis of HF as the specific pathology can determine subsequent treatment. Most commonly, HF is due to myocardial dysfunction: either systolic, diastolic, or both. However, pathology of the valves, pericardium, and endocardium, and abnormalities of heart rhythm and conduction can also cause or contribute to HF.

Cardiomyopathies are defined by the WHO as diseases of the myocardium associated with cardiac dysfunction, Cardiomyopathies are categorized into dilated, restrictive, hypertrophic, and unclassified based on the predominant pathophysiologic characteristics. A new category has been added to include right ventricular abnormalities. The disorders that are associated with systemic or certain cardiac diseases are called specific heart muscle diseases and include ischemic cardiomyopathy, valvular, hypertensive, inflammatory, metabolic, peripartal, general systemic disease, muscular dystrophies, neuromuscular disorders, and toxic and hypersensitivity reactions. The unclassified cardiomyopathy category includes disorders such as fibroelastosis, noncompacted myocardium, and systolic dysfunction with minimal dilation.

Patiant admitted in I.C.U. with heart failure who already have cardiomyopathy Some patiants discharge without any comorbidies and some acquire renal failure, respiratory failure,MCS, sepsis, and some were associated with mortality . Significant comorbidities associated with these hospitalizations included arrhythmias, renal failure , cerebrovascular disease, and hepatic impairment.

Study Timeline

• Study First Submitted: 2022-09-27
• Status Verified: 2022-10
• Study First Submitted QC: 2022-10-01
• Last Update Submitted: 2022-10-04
• Study First Posted: 2022-10-05
• Last Update Posted: 2022-10-06
• Study Start: 2023-09
• Primary Completion: 2024-09
• Study Completion: 2024-10

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Cardiomyopathic patiants admitted with heart failure diagonsed clinicaly , by Echocardiograph , or by ECG.

1. Dilated cardiomyopathy[ Unknown, Uremic cardiomyopathy, Post-partum, Ishemic].
2. Hypertrophic cardiomyopathy.
3. Acute heart failure caused by A.C.S. , Toxic myocardititis.

Exclusion Criteria

1. Heart failure due to valvular heart disease.
2. Heart failure caused by hypertension.
3. patiant with COPD

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Effect on E.F.	through study completion, an average of 1 year	Degree of impairement of E.F.
Sepsis	through study completion, an average of 1 year	Who developed sepsis and its effect on cardiac function.
Effect on renal function	through study completion, an average of 1 year	Who developed renal impairement, and its effect on cardiac function.
Effect on liver function	through study completion, an average of 1 year	Who suffer liver function impairement, improvement or deteroriation